IL17A and systemic lupus erythematosus: An interesting corollary to the investigation of sCTLA-4 blockade on peptides was the same assessment of the effects on recall responses in lupus patients compared with healthy donors, where healthy donor PBMC were enhanced to PPD recall antigen following sCTLA-4 inhibition (Fig. 5 and Table 2), but there were no significant changes in levels of IL-17 or IL-10 following blockade of sCTLA-4.